MAPT and Alzheimer disease: Importantly, in the previous cohort, CSF Ng offered a predictive value for future cognitive impairment in cognitively normal individuals over a 2-3 year follow-up period that was comparable to other biomarkers of AD pathology (CSF tau, p-tau181, and Aβ42).